Stratasys reported first quarter 2026 financial results showing 18% year-over-year revenue growth, reaching $171 million. The company's medical device and aerospace segments were the primary growth drivers, reflecting increasing adoption of additive manufacturing in regulated industries.
Medical Segment Leads Growth
The medical device manufacturing segment grew 31% compared to the same period last year. Stratasys' PolyJet and SAF (Spread Film Array Fusion) technologies continue to gain traction for patient-specific surgical guides, dental aligners, and hearing aid components. The company's FDA-compliant workflows have accelerated qualification processes for medical manufacturers.
Aerospace Certification Progress
Aerospace applications accounted for 24% of total revenue, with several major Tier-1 suppliers expanding their use of Stratasys systems for flight-certified parts. The company's material portfolio now includes 12 FAA/EASA-approved thermoplastics for aerospace interiors and functional components.
Industrial Polymer Adoption
The company's FDM and Origin P3 platforms saw strong demand from industrial customers seeking alternatives to traditional injection molding for low-volume production. Notable wins included contracts with automotive OEMs for custom tooling and functional prototyping.
Outlook
Stratasys raised its full-year guidance, projecting 15-17% revenue growth for fiscal 2026. CEO Yoav Zilber stated that the company's focus on "production-grade additive manufacturing" positions it well for continued penetration in high-value industry segments.
Looking for 3D printing services?
PrintVX.com provides professional 3D printing services with fast turnaround. Get an instant quote today -- no minimum order required.
Ready to Get Your Custom Parts?
PrintVX offers professional 3D printing and CNC machining services. From prototyping to low-volume production -- fast turnaround, competitive pricing.
Get a Free Quote at PrintVX.com →